Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study
Abstract Sorafenib improves outcomes in adult hepatocellular carcinoma; however, hand foot skin reaction (HFSR) is a dose limiting toxicity of sorafenib that limits its use. HFSR has been associated with sorafenib systemic exposure. The objective of this study was to use modeling and simulation to d...
Guardado en:
Autores principales: | John C. Panetta, Olivia Campagne, Jessica Gartrell, Wayne Furman, Clinton F. Stewart |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fa3bdba6f6544244bf67514913dc3bc8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
por: Olivier Mir, et al.
Publicado: (2012) -
Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Junji Furuse
Publicado: (2008) -
Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
por: Foskett A, et al.
Publicado: (2017) -
Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
por: Kung-Hao Liang, et al.
Publicado: (2021) -
Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles
por: Zhang H, et al.
Publicado: (2012)